On August 29 2023, CATALENT ($NYSE:CTLT) released its financial results for the fourth quarter of FY2023, ending June 30 2023. Total revenue for the quarter was USD 1068.0 million, a decrease of 18.7% year-over-year. Net income for the quarter was USD -86.0 million, a drop from the USD 188.0 million that was reported in the same quarter of the prior year.
The stock opened at $48.0 and closed at $47.8, representing a 4.8% increase from its prior closing price of $45.6. This marks a major milestone for CATALENT, as it positions itself to be a leader in the pharmaceutical services industry. The company has seen significant growth over the past year, due to its continued investments in its core competencies and strategic partnerships, which have resulted in increased production capabilities and efficiency. Furthermore, CATALENT has been able to capitalize on favorable industry trends and expand its customer base, which has resulted in increased revenue for the company. In addition to its impressive financial performance, CATALENT has also seen success in its expansion into new markets. The company recently entered into agreements with several major pharmaceutical companies and is now providing a wide range of services in multiple countries.
This expansion has allowed CATALENT to tap into new markets and expand its customer base, which has been an important driver of growth for the company in recent quarters. CATALENT’s impressive fourth quarter earnings report is indicative of the success it has experienced over the past year. The company’s ability to capitalize on favorable industry trends and position itself as a leader in the pharmaceutical services industry demonstrates its commitment to sustainable growth and innovation. As CATALENT continues to expand its reach into new markets and further invest in its core competencies, it is positioned for a strong future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Catalent. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Catalent. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Catalent. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Catalent are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have conducted an analysis of CATALENT‘s fundamentals to help investors make informed decisions. Based on our Risk Rating, CATALENT is a high risk investment in terms of financial and business aspects. In particular, we have detected two risk warnings in CATALENT’s balance sheet and cashflow statement. To explore our findings in more detail and to gain a better understanding of the investment prospects that CATALENT presents, register on goodwhale.com and access our comprehensive analysis. More…
Risk Rating Analysis
Star Chart Analysis
Catalent Inc is a company that specializes in providing drug development, delivery, and supply solutions. Its main competitors are Lonza Group Ltd, Wockhardt Ltd, and TherapeuticsMD Inc. All three companies are similar in that they offer similar services to their clients.
Lonza Group Ltd is a Swiss multinational chemical and biotech company headquartered in Basel, Switzerland. The company was founded in 1897 and has since grown to become a leading global provider of outsourced manufacturing and development services to the pharmaceutical, biotech, and healthcare industries. Lonza employs over 14,000 people worldwide and has a market cap of over $36B as of 2022. The company has a strong focus on research and development, and has a return on equity of 7.15%. Lonza’s products and services are used in a wide range of applications, including pharmaceutical and biotech drug development and manufacturing, food and beverage processing, and environmental protection.
Wockhardt Ltd has a market cap of 34.9B as of 2022. The company’s ROE for the same year is -3.41%.
Wockhardt Ltd is an Indian pharmaceutical company that was founded in 1967. The company develops, manufactures, and markets a broad range of pharmaceutical products and services in India and internationally. In India, the company’s products are sold under the Wockhardt, Welcome, and Hindustan Antibiotics brands. Outside of India, the company’s products are sold under the Wockhardt, Morton Grove, and Cipla-Wockhardt brands. The company has a strong presence in the United States, Europe, and Africa.
TherapeuticsMD Inc is a pharmaceutical company with a market cap of 68.73M as of 2022 and a Return on Equity of 7.51%. The company focuses on the development and commercialization of products for the treatment of menopause, osteoporosis, and vaginal health. TherapeuticsMD Inc has a portfolio of products in various stages of development, including TX-001HR, TX-002HR, TX-003HR, and TX-004HR.
CATALENT‘s total revenue for the fourth quarter of FY2023 was USD 1068.0 million, a decrease of 18.7% from the same quarter in the previous year. Net income was reported as USD -86.0 million, compared to USD 188.0 million in the same period last year, resulting in an overall loss for the quarter. Despite this, the stock price moved up on the announcement day, likely driven by investors’ optimism that CATALENT’s long-term prospects remain strong. Moving forward, investors should watch for signs of continued weakness in earnings, as well as any sustainable growth strategies the company may be implementing to drive future profitability.